08:10 PM Oct 11th
IDEAL-ICU Trial: Patents with severe AKI, early septic shock, no life threatening indication for RRT - early RRT not associated with improved 90-d mortality or secondary outcomes, compared to delayed RRT (48-hrs) Delayed RRT 38% of patients not receiving RRT.
04:10 PM Oct 10th
JAMA: Polymyxin B hemoperfusion was not effective in reducing 28-d mortality in septic shock in patients with elevated endotoxin activity.
03:10 PM Oct 10th
NEJM: Outbreak C.auris in neuro-ICU, persistence on reusable skin-surface probes, resistance to fluconazole, voriconazole, posiconazole, with 18% resistance to amphotericin. Hard to decolonize, invasive infections uncommon, no deaths attributed.
07:09 PM Sep 25th
JAMA Merino Trial - piperacillin-tazobactam not noninferior to meropenem for ceftriaxone resistanct E.coli or Klebs bacteraemia for 30-d mortality. Does not support piperacillin-tazobactam over meropenem for these infections. How to reduce carbapenem use?
08:09 AM Sep 22nd
Aug JC Podcast available on Crit-IQ and iTunes
Crit-IQ is proud to provide free access to developing or under-resourced countries. Currently this includes East Timor, Fiji, Cook Islands, Samoa, Tonga, Vanuatu and Zambia. We are also a member of the HINARI network.
New Open Access Blog Topics